RUA Medical

RUA Life Sciences is a publicly traded medical device company formed in 2020 through the strategic merger of AorTech International plc and RUA Medical Devices Ltd. Its mission is to improve patient outcomes by exploiting its flagship biomaterial, Elast-Eon™, a leading long-term implantable polyurethane. The company's strategy is executed through a diversified, four-pillar business model encompassing technology licensing, contract development and manufacturing (CDMO), and proprietary product development in vascular and structural heart applications. This integrated approach aims to de-risk operations and capture value across the medical device value chain.

Elast-Eon™, a family of silicone-polyurethane copolymers designed as a long-term implantable biomaterial combining the strength of polyurethanes with the biostability of silicones.

Faces different competitors in each segment: material suppliers (DSM, Lubrizol) in licensing; other CDMOs in manufacturing; and giants like Gore, Getinge, Edwards Lifesciences, and Medtronic in its target product markets. Its deep, owned material science is a differentiator but requires clinical proof to challenge established standards of care.